Fosdevirine
Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS.
≈ 3 min read
Fosdevirine. encyclopegia.org, snapshot enwiki-001330818530. /a/fosdevirine
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS.[1][2]
It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued[3][4] due to unexpected side effects.[5]
References
edit edit source- ^ Dousson C, Alexandre FR, Amador A, Bonaric S, Bot S, Caillet C, et al. (March 2016). "Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor". Journal of Medicinal Chemistry. 59 (5): 1891–8. doi:10.1021/acs.jmedchem.5b01430. PMID 26804933. Wikipedia revision 1330818530, retrieved 2026-11-19
- ^ "Fosdevirine". AIDSinfo. U.S. National Library of Medicine, U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-08-14. Wikipedia revision 1330818530, retrieved 2026-11-19
- ^ "Fosdevirine". Adis Insight. Springer Nature Switzerland AG. Highest Development Phases: Discontinued, HIV-1 infections Wikipedia revision 1330818530, retrieved 2026-11-19
- ^ "Fosdevirine". MedKoo Biosciences. GSK2248761 is no longer in clinical development. Wikipedia revision 1330818530, retrieved 2026-11-19
- ^ Margolis DA, Eron JJ, DeJesus E, White S, Wannamaker P, Stancil B, Johnson M (2013). "Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)". Antiviral Therapy. 19 (1): 69–78. doi:10.3851/IMP2689. PMID 24158593. S2CID 6147197. Wikipedia revision 1330818530, retrieved 2026-11-19
(Discovery and development)
(Integrase strand transfer inhibitors (INSTI))
(Discovery and development)
inhibitors (RTIs)
- Abacavir/lamivudine#
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Bictegravir/emtricitabine/tenofovir alafenamide°
- Bictegravir/lenacapavir
- Cabotegravir/rilpivirine
- Darunavir/cobicistat
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
- Dolutegravir/emtricitabine/tenofovir alafenamide
- Dolutegravir/lamivudine°
- Dolutegravir/lamivudine/tenofovir alafenamide°
- Dolutegravir/lamivudine/tenofovir disoproxil°#
- Dolutegravir/rilpivirine
- Doravirine/islatravir
- Doravirine/lamivudine/tenofovir disoproxil
- Efavirenz/emtricitabine/tenofovir disoproxil#
- Efavirenz/lamivudine/tenofovir disoproxil#
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
- Emtricitabine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir disoproxil
- Emtricitabine/tenofovir disoproxil#
- Lamivudine/nevirapine/stavudine
- Lamivudine/nevirapine/zidovudine
- Lamivudine/raltegravir
- Lamivudine/tenofovir disoproxil#
- Lamivudine/zidovudine#
- Lopinavir/ritonavir#
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330818530 under CC BY-SA 4.0; modifications have been made.